No profile data available.
X4 Pharmaceuticals, Inc. (XFOR) is a healthcare company in the immunodeficiency treatment drugs industry, based in Boston, United States, with about 45 full-time employees.
It reported revenue of $35.11 million for fiscal year 2025, up 1273.2% from fiscal year 2024, and net income of -$79.20 million. United Kingdom was its largest region in fiscal year 2025, with 81% of revenue. Its market capitalization was $276.62 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
, a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
X4 Pharmaceuticals reported $35.11 million in revenue for fiscal year 2025, up 1273.2% from $2.56 million in fiscal year 2024.
United Kingdom: 81% of revenue by region in fiscal year 2025, followed by United States (19%).
$276.62 million as of October 8, 2026.
Listed companies of a similar size in the same industry (immunodeficiency treatment drugs) include BioCryst Pharmaceuticals, Inc. (BCRX), Pharvaris N.v. (PHVS), Pharming Group N.v. (PHAR), AIM ImmunoTech Inc. (AIM).